Four key points:
1. On March 21, the FDA alerted healthcare providers and patients about vulnerabilities associated with communication between Medtronic’s implantable cardiac devices, clinic programmers and home monitors.
“Although the system’s overall design features help safeguard patients, Medtronic is developing updates to further mitigate these cybersecurity vulnerabilities,” states the warning.
2. The FDA recommended continued use of the devices, Medtronic’s implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators, as indicated. The company’s programmer and monitors models are also affected, including CareLink 2090 Programmer, MyCareLink Monitor models 24950 and 24952, and CareLink Monitor Model 2490C.
3. The FDA has not received reports of patient harm related to the potential cybersecurity vulnerabilities.
4. In collaboration with the FDA, Medtronic is creating and implementing security updates and plans to provide more information to the public when it’s available.
More articles on devices:
10 key players in the global spine surgery robots market
Nordic Capital acquires international orthopedic company: 3 notes
Zimmer Biomet earns FDA clearance for Rosa One Spine System – 4 insights
